In the Claims:

Please amend claims 1, 10, 11-13, 29 and 41 and please cancel claims 2-9, 18-28 and 45-124 without prejudice or disclaimer. The following listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently Amended) A pharmaceutical composition ~~comprising:~~consisting of an isolated heat shock protein (HSP) of SEQ ID NO:3~~or heat shock protein-like protein (HSPLP)~~, or a fragment thereof consisting of SEQ ID NO: 47, in an effective amount to promote fugetactic activity and a pharmaceutically acceptable carrier.

2. – 9. (Cancelled)

10. (Currently Amended) The pharmaceutical composition of claim 1, wherein the HSP ~~or HSPLP~~ is in a secreted form.

11. (Currently Amended) The pharmaceutical composition of claim 10, wherein the secreted form of the HSP~~LP~~ comprises a signal sequence or a secretory sequence.

12. (Currently Amended) The pharmaceutical composition of claim 1, wherein the HSP ~~or HSPLP~~ is from a stressed or a non-stressed cell.

13. (Currently Amended) The pharmaceutical composition of claim 1, wherein the HSP ~~or HSPLP~~ is from a tumor or a tumor cell line.

14. (Original) The pharmaceutical composition of claim 13, wherein the tumor or tumor cell line is a hematological tumor or a hematological tumor cell line.

15. (Original) The pharmaceutical composition of claim 14, wherein the hematological tumor or hematological tumor cell line is a leukemia or a lymphoma.

16. (Original) The pharmaceutical composition of claim 15, wherein the lymphoma is a thymoma.

17. (Original) The pharmaceutical composition of claim 14, wherein the hematological tumor cell line is EL4.

18. – 28. (Cancelled)

29. (Currently Amended) A method of promoting fugetaxis of migratory cells in a subject, comprising: administering to a subject in need of such treatment the Heat Shock Protein (HSP) ~~HSP, HSPLP, L-plastin or LPLP~~ of SEQ ID NO~~s~~:3~~-8,~~ or a fragment thereof consisting of SEQ ID NO: 47, in an amount effective to promote fugetaxis of migratory cells away from a specific site in a subject.

30. (Original) The method of claim 29, further comprising co-administering a non-fugetactic therapeutic agent.

31. (Original) The method of claim 30, wherein the non-fugetactic agent is an anti-inflammatory or an anti-allergic agent.

32. (Original) The method of claim 29, wherein the specific site is a site of an inflammation.

33. (Original) The method of claim 29, wherein the specific site is a medical device, prosthetic device or a transplanted organ or tissue.

34. (Original) The method of claim 33, wherein the medical device, prosthetic device or a transplanted organ or tissue is xenogeneic, stem-cell derived, synthetic or an allograft.

35. (Original) The method of claim 33, wherein the medical device, prosthetic device or a transplanted organ or tissue is a stent.

36. (Original) The method of claim 29, wherein the specific site is a site of an autoimmune reaction.

37. (Original) The method of claim 36, wherein the site of an autoimmune reaction is a site at or near a joint.

38. (Original) The method of claim 29, wherein the specific site is a site of an allergic reaction.

39. (Original) The method of claim 29, wherein the pharmaceutical composition is administered locally.

40. (Original) The method of claim 29, wherein the pharmaceutical composition is administered systemically.

41. (Currently Amended) The method of claim 29, wherein the HSP~~, HSPLP, L-plastin or LPLP~~ is conjugated to a targeting molecule.

42. (Original) The method of claim 29, wherein the migratory cells are hematopoietic cells.

43. (Original) The method of claim 42, wherein the hematopoietic cells are immune cells.

44. (Original) The method of claim 43, wherein the immune cells are T cells.

45. – 124. (Cancelled)